Show simple item record

dc.contributor.authorDuggan-Keen, Margaret F
dc.contributor.authorBrown, Michael D
dc.contributor.authorStacey, Simon N
dc.contributor.authorStern, Peter L
dc.date.accessioned2010-02-24T14:08:58Z
dc.date.available2010-02-24T14:08:58Z
dc.date.issued1998-12-01
dc.identifier.citationPapillomavirus vaccines. 1998, 3:D1192-208 Front. Biosci.en
dc.identifier.issn1093-4715
dc.identifier.pmid9835649
dc.identifier.urihttp://hdl.handle.net/10541/92936
dc.description.abstractThe considerable morbidity and mortality associated with certain human papillomaviruses (HPV) has provided the impetus for HPV vaccine development. The design of such vaccines has evolved from an understanding of the nature of HPV infections and their consequences, together with evaluation of the efficacy of different approaches to vaccination in animal models. These studies have culminated in the production of several different vaccine preparations which are currently undergoing Phase I and II clinical trials. The justification for the widespread implementation of prophylactic HPV vaccines will depend on the outcome of larger scale studies of vaccine efficacy that take into account the epidemiology of HPV infections and associated disease. The usefulness of therapeutic HPV vaccines will require evidence that they can substantially augment or substitute for the effectiveness of currently available treatments.
dc.language.isoenen
dc.subjectTumour Virus Infectionsen
dc.subjectUterine Cervical Canceren
dc.subject.meshAntigens, Viral
dc.subject.meshBacteria
dc.subject.meshClinical Trials as Topic
dc.subject.meshDNA, Viral
dc.subject.meshDendritic Cells
dc.subject.meshDisease Models, Animal
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunity, Innate
dc.subject.meshPapillomaviridae
dc.subject.meshPapillomavirus Infections
dc.subject.meshPapillomavirus Vaccines
dc.subject.meshPeptides
dc.subject.meshTumor Virus Infections
dc.subject.meshUterine Cervical Neoplasms
dc.subject.meshVaccines, DNA
dc.subject.meshViral Proteins
dc.subject.meshViral Vaccines
dc.subject.meshVirion
dc.titlePapillomavirus vaccines.en
dc.typeArticleen
dc.contributor.departmentPaterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, United Kingdom.en
dc.identifier.journalFrontiers in Bioscienceen
html.description.abstractThe considerable morbidity and mortality associated with certain human papillomaviruses (HPV) has provided the impetus for HPV vaccine development. The design of such vaccines has evolved from an understanding of the nature of HPV infections and their consequences, together with evaluation of the efficacy of different approaches to vaccination in animal models. These studies have culminated in the production of several different vaccine preparations which are currently undergoing Phase I and II clinical trials. The justification for the widespread implementation of prophylactic HPV vaccines will depend on the outcome of larger scale studies of vaccine efficacy that take into account the epidemiology of HPV infections and associated disease. The usefulness of therapeutic HPV vaccines will require evidence that they can substantially augment or substitute for the effectiveness of currently available treatments.


This item appears in the following Collection(s)

Show simple item record